Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
Fractyl Health announced new U.S. patent additions strengthening the intellectual property foundation for Revita as it prepares an FDA De Novo marketing submission for post-GLP-1 weight maintenance. The USPTO issued a catheter patent (U.S. Patent No.
Key figures
- Us patents granted
- 39
- Pending us applications
- 40
- Catheter patent term end
- November 28, 2042
- International patents issued
- 50
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.